問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Endocrinology

Division of Cardiovascular Diseases

Division of General Internal Medicine

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Endocrinology

更新時間：2023-09-19

謝安慈HSIEH, AN-TSZ
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝安慈

List

16Cases

2004-01-01 - 2004-12-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-08-01 - 2011-07-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-04-01 - 2011-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-10-01 - 2010-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-06-01 - 2016-01-31

Phase III

Completed
A Phase 3, Open Label, Randomized, Parallel, 26-Week Treatment Study Comparing LY2605541 with Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Asian Insulin Naïve Patients with Type 2 Diabetes Mellitus

  • Condition/Disease

    Type II DM

  • Test Drug

    (LY2605541)

Participate Sites
9Sites

Terminated9Sites

2013-04-01 - 2015-06-30

Phase III

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NAÏVE TO ANTI-HYPERGLYCEMIC THERAPY

  • Condition/Disease

    TYPE 2 DIABETES

  • Test Drug

    Aleglitazar (RO0728804)

Participate Sites
3Sites

Terminated3Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-02-01 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2013-03-01 - 2015-07-31

Phase III

A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    MK-3102

Participate Sites
16Sites

Terminated16Sites

2014-04-22 - 2017-10-04

Phase III

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN ASIAN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY

  • Condition/Disease

    TYPE 2 DIABETES

  • Test Drug

    Ertugliflozin (MK-8835/PF-04971729)

Participate Sites
11Sites

Terminated11Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB